Resources
29 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 6/14/2022 (updated 3/27/2024)
In 2019, the National Institutes of Health (NIH) began supporting research on treatment for opioid use disorder in criminal justice settings. The Justice Community Opioid Innovation Network (JCOIN) studies the effectiveness of new medications and other interventions as part of the NIH HEAL Initiative – Helping to End Addiction Long-Term.
Posted 4/26/2022 (updated 3/27/2024)
Overview of the jail-based Medication Assisted Treatment program within the Adult Detention Center in Fairfax County, Virginia.
Posted 3/23/2022 (updated 3/27/2024)
Over the past 20 years, drug overdose deaths have increased dramatically in the United States. Most of these deaths involved opioids, including prescription pain medications, heroin, and synthetic opioids such as fentanyl. These are called opioid-related overdoses and often occur as a result of respiratory depression caused by opioids, even when other medications and drugs are involved.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 3/14/2022 (updated 3/27/2024)
Substance use and its progression to impairment, loss of control, and development of substance use disorders is a significant problem for adolescents and young adults. This presentation will provide an overview of developmentally-informed approaches to engaging youth and their families in treatment.
Learning Objectives:
Recognize motivational approaches to working with substance involved youth
Identify approaches to engaging families of substance involved youth
Speaker: Marc Fishman, MD
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/28/2021 (updated 4/2/2024)
This handbook is intended to address this particular set of workplace issues- namely those that arise from experiences of loss, grief and trauma. These issues can surface within the workplace itself, or can be imported into the work setting from workers’ personal lives. This handbook will be useful for managers, supervisors and human resource specialists who are interested in developing their understanding of how the very real issues associated with loss, grief and trauma can be tackled when they show up in work settings. This handbook is a blend of theory and practice, and can be used as a resource for building effective policies and practical responses to the complexities of managing grief, loss and bereavement in the workplace.